Skip to main content

Can you take Cold & Hot with Eliglustat?

1 drug interaction and 4 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Minor drug interactions

Minor:

menthol topical eliglustat

Applies to: Cold & Hot (menthol topical) and eliglustat

Coadministration with orally administered menthol may decrease plasma concentrations of drugs that are substrates of the CYP450 3A4 and/or CYP450 2C9 isoenzymes. The proposed mechanism is increased clearance due to menthol-mediated induction of CYP450 3A4 and CYP450 2C9. In vivo data suggests that concomitant administration of oral menthol reduced the systemic exposure (AUC) of triazolam (a CYP450 3A4 substrate) by 40%, and phenytoin (a CYP450 2C9 substrate) by 20%. Until further data are available, no specific precautions are recommended.

The information above is from our professional interaction data. Consumer information is not available for this interaction.

Food/lifestyle interactions

Major food/lifestyle interactions

Major:

eliglustat Food/Lifestyle

Applies to: eliglustat

Do not consume grapefruit or grapefruit juice during treatment with eliglustat unless directed otherwise by your doctor.

Grapefruit juice can increase the blood levels of eliglustat to dangerous levels.

This may increase the risk of serious and potentially life-threatening cardiac side effects such as:

  • irregular heart rhythm
  • heart block
  • cardiac arrest

Talk to your doctor if you have any questions or concerns.

You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

3 potential interactions Applies to: 3 conditions, including Heart Disease, Liver Disease, and Renal Dysfunction.

Heart Disease

Major:

eliglustat

Eliglustat has a major potential interaction with Heart Disease.

The use of eliglustat is contraindicated in patients who are CYP2D6 extensive metabolizers or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor or those who are intermediate metabolizers or poor metabolizers taking a strong CYP3A inhibitor due to the risk of a significant increase in drug plasma concentrations. Eliglustat is predicted to cause increases in EKG intervals (PR, QTc, and QRS) at high plasma concentrations and could result in arrhythmias; therefore, its use is not recommended in patients with preexisting cardiac disease (congestive heart failure, recent myocardial infarction, heart block, arrhythmias), or long QT syndrome.

Liver Disease

Major:

eliglustat

Eliglustat has a major potential interaction with Liver Disease.

The use of drugs eliglustat is contraindicated in patients with moderate or severe hepatic impairment and in those patients, who are CYP450 2D6 extensive metabolizers with mild hepatic impairment and taking a strong or moderate CYP450 2D6 inhibitor due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals. This agent is contraindicated in patients who are CYP450 2D6 extensive metabolizers, intermediate metabolizers and taking a strong or moderate CYP450 2D6 inhibitor concomitantly with a strong or moderate CYP450 3A inhibitor. In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat is contraindicated in those patients with any degree of hepatic impairment or those taking a strong CYP450 3A inhibitor.

Renal Dysfunction

Major:

eliglustat

Eliglustat has a major potential interaction with Renal Dysfunction.

The use of drugs eliglustat should be avoided in patients with end-stage renal disease (estimated creatinine clearance (eCrCl) less than 15 mL/min not on dialysis or requiring dialysis). No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCrCl at least 15 mL/min). In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat should be avoided in those patients with any degree of renal impairment.

Report options

Loading...
QR code containing a link to this page

More resources

Cold & Hot

A total of 364 drugs are known to interact with Cold & Hot.

eliglustat

A total of 383 drugs are known to interact with eliglustat.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer